Evidence map›Paper›PMID 42023031›Full record

ArticleMolecular therapy. Nucleic acids2026

Vacuolar ATPase subunit Atp6v0c transgene promotes neuroprotection and long-distance axon regeneration in injured retinal ganglion neurons.

Anja Kearney, Agnieszka Lukomska, Jacob Brady, Ashiti Damania, Mahit Gupta, Ephraim F Trakhtenberg

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anja KearneyDepartment of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030, USA.
Agnieszka LukomskaDepartment of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030, USA.
Jacob BradyDepartment of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030, USA.
Ashiti DamaniaDepartment of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030, USA.
Mahit GuptaDepartment of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030, USA.
Ephraim F TrakhtenbergDepartment of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030, USA.

Funding

Small non-coding RNAs regulate retinal ganglion cell maturation and the developmental loss of intrinsic axon growth capacityR01EY029739 · NEI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI TRAKHTENBERG, FELIKS EPHRAIM · 2019 to 2023
$2.1M
NEI NIH HHS R01 EY029739
6 · The paper itself

Abstract

Central nervous system (CNS) projection neurons' failure to repair or regenerate injured axons has devastating consequences for those who have sustained CNS injuries. Thus, there is a need for translatable factors capable of promoting long-distance axon regeneration in the CNS. We hypothesized that supporting lysosomes in injured neurons by supplementing their structural factors through gene therapy may foster axon regeneration. To test our hypothesis, we selected Atp6v0c for experimental regulation because it plays roles in lysosomal acidification and the degradation of misfolded proteins in response to endoplasmic reticulum (ER) stress in injured neurons. We tested this in a rodent optic nerve crush (ONC) model of traumatic optic neuropathy (TON), in which injured prototypical CNS projection neurons, the retinal ganglion cells (RGCs), do not regenerate damaged axons and eventually degenerate. Atp6v0c transgene expression was achieved using intravitreally injected adeno-associated virus serotype 2 (AAV2), which transduces the RGCs. For benchmarking, we compared efficacy to AAV2 targeting of prominent regulators of axon regeneration, Pten, and Klf9. We found that Atp6v0c transgene promoted RGC survival and long-distance axon regeneration, comparable to targeting Pten and Klf9. Thus, Atp6v0c is an axon regeneration-promoting factor with potential for treating CNS injury and disease.

Indexed as

axon regenerationgene therapyMT: Oligonucleotides: Therapies and Applicationsoptic nerve injuryretinal ganglion cell

Identifiers

PMID42023031
PMCPMC13096995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.